Cargando…
Rifabutin as salvage therapy for Helicobacter pylori eradication: Cornerstones and novelties
When several Helicobacter pylori eradication treatments fail, guidelines recommend a cultured guided approach; however, culture is not widely available. Therefore, a rifabutin based regimen could be the best solution. Rifabutin indeed shows a low rate of antibiotic resistance. Rifabutin is generally...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753051/ https://www.ncbi.nlm.nih.gov/pubmed/36533106 http://dx.doi.org/10.3748/wjg.v28.i45.6356 |
_version_ | 1784850879819546624 |
---|---|
author | Borraccino, Antonia Valeria Celiberto, Francesca Pricci, Maria Girardi, Bruna Iannone, Andrea Rendina, Maria Ierardi, Enzo Di Leo, Alfredo Losurdo, Giuseppe |
author_facet | Borraccino, Antonia Valeria Celiberto, Francesca Pricci, Maria Girardi, Bruna Iannone, Andrea Rendina, Maria Ierardi, Enzo Di Leo, Alfredo Losurdo, Giuseppe |
author_sort | Borraccino, Antonia Valeria |
collection | PubMed |
description | When several Helicobacter pylori eradication treatments fail, guidelines recommend a cultured guided approach; however, culture is not widely available. Therefore, a rifabutin based regimen could be the best solution. Rifabutin indeed shows a low rate of antibiotic resistance. Rifabutin is generally used in combination with amoxicillin in a triple therapy, with eradication rates about 80% in third-line regimens. The ideal duration of this therapy should range between 10 and 12 d. Combinations with antibiotics other than amoxicillin have demonstrated even better results, such as vonoprazan, which is a type of novel acid suppressor drug. Finally, a new formulation of triple therapy in a single capsule is under investigation, which is a field that deserves further investigation. Some notes of caution about rifabutin should be mentioned. This drug is used to treat tuberculosis or atypical mycobacteria; therefore, before starting a rifabutin-based eradication regimen, Mycobacterium tuberculosis infection should be thoroughly tested, since its use could promote the development of antibiotic resistance, thus affecting its effectiveness against Koch’s bacillus. Additionally, some serious side effects must be evaluated before starting any rifabutin-based therapy. Adverse effects include fever, nausea, vomiting and bone marrow suppression. For this reason, full blood count surveillance is required. |
format | Online Article Text |
id | pubmed-9753051 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-97530512022-12-16 Rifabutin as salvage therapy for Helicobacter pylori eradication: Cornerstones and novelties Borraccino, Antonia Valeria Celiberto, Francesca Pricci, Maria Girardi, Bruna Iannone, Andrea Rendina, Maria Ierardi, Enzo Di Leo, Alfredo Losurdo, Giuseppe World J Gastroenterol Minireviews When several Helicobacter pylori eradication treatments fail, guidelines recommend a cultured guided approach; however, culture is not widely available. Therefore, a rifabutin based regimen could be the best solution. Rifabutin indeed shows a low rate of antibiotic resistance. Rifabutin is generally used in combination with amoxicillin in a triple therapy, with eradication rates about 80% in third-line regimens. The ideal duration of this therapy should range between 10 and 12 d. Combinations with antibiotics other than amoxicillin have demonstrated even better results, such as vonoprazan, which is a type of novel acid suppressor drug. Finally, a new formulation of triple therapy in a single capsule is under investigation, which is a field that deserves further investigation. Some notes of caution about rifabutin should be mentioned. This drug is used to treat tuberculosis or atypical mycobacteria; therefore, before starting a rifabutin-based eradication regimen, Mycobacterium tuberculosis infection should be thoroughly tested, since its use could promote the development of antibiotic resistance, thus affecting its effectiveness against Koch’s bacillus. Additionally, some serious side effects must be evaluated before starting any rifabutin-based therapy. Adverse effects include fever, nausea, vomiting and bone marrow suppression. For this reason, full blood count surveillance is required. Baishideng Publishing Group Inc 2022-12-07 2022-12-07 /pmc/articles/PMC9753051/ /pubmed/36533106 http://dx.doi.org/10.3748/wjg.v28.i45.6356 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Minireviews Borraccino, Antonia Valeria Celiberto, Francesca Pricci, Maria Girardi, Bruna Iannone, Andrea Rendina, Maria Ierardi, Enzo Di Leo, Alfredo Losurdo, Giuseppe Rifabutin as salvage therapy for Helicobacter pylori eradication: Cornerstones and novelties |
title | Rifabutin as salvage therapy for Helicobacter pylori eradication: Cornerstones and novelties |
title_full | Rifabutin as salvage therapy for Helicobacter pylori eradication: Cornerstones and novelties |
title_fullStr | Rifabutin as salvage therapy for Helicobacter pylori eradication: Cornerstones and novelties |
title_full_unstemmed | Rifabutin as salvage therapy for Helicobacter pylori eradication: Cornerstones and novelties |
title_short | Rifabutin as salvage therapy for Helicobacter pylori eradication: Cornerstones and novelties |
title_sort | rifabutin as salvage therapy for helicobacter pylori eradication: cornerstones and novelties |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753051/ https://www.ncbi.nlm.nih.gov/pubmed/36533106 http://dx.doi.org/10.3748/wjg.v28.i45.6356 |
work_keys_str_mv | AT borraccinoantoniavaleria rifabutinassalvagetherapyforhelicobacterpylorieradicationcornerstonesandnovelties AT celibertofrancesca rifabutinassalvagetherapyforhelicobacterpylorieradicationcornerstonesandnovelties AT priccimaria rifabutinassalvagetherapyforhelicobacterpylorieradicationcornerstonesandnovelties AT girardibruna rifabutinassalvagetherapyforhelicobacterpylorieradicationcornerstonesandnovelties AT iannoneandrea rifabutinassalvagetherapyforhelicobacterpylorieradicationcornerstonesandnovelties AT rendinamaria rifabutinassalvagetherapyforhelicobacterpylorieradicationcornerstonesandnovelties AT ierardienzo rifabutinassalvagetherapyforhelicobacterpylorieradicationcornerstonesandnovelties AT dileoalfredo rifabutinassalvagetherapyforhelicobacterpylorieradicationcornerstonesandnovelties AT losurdogiuseppe rifabutinassalvagetherapyforhelicobacterpylorieradicationcornerstonesandnovelties |